米国市場銘柄情報

ABEO アベオナ・セラピューティクス

銘柄追加

3.2600
+0.0700+2.19%

終値 04/26 16:00 ET

3.4288
+0.1688+5.18%

市場前 09:05 ET

8,917.74万時価総額-1288直近PER

アベオナ・セラピューティクスに関するコメント

ログインコメントを投稿

Trytosaveabit

04/26 21:20

Insider buys

$アベオナ・セラピューティクス(ABEO.US)$ Officer O'Malley Brendan M. purchased 8,600 shares of common stock on Apr 25, 2024 at an average price of $3.24 for a total value of $27,864. Officer Vazzano Joseph Walter purchased 5,608 shares of common stock on Apr 25, 2024 at an average price of $3.14 for a total value of $17,609.12.

Stock_Drift

04/25 08:25

$アベオナ・セラピューティクス(ABEO.US)$

M3LANI3

04/24 22:23

$アベオナ・セラピューティクス(ABEO.US)$ She’s getting clobbered today

Stock_Drift

04/24 07:36

#lux #thecramps

$アベオナ・セラピューティクス(ABEO.US)$

Stock_Drift

04/24 05:50

$アベオナ・セラピューティクス(ABEO.US)$

Sean Parker

04/24 05:40

possible up swing

$アベオナ・セラピューティクス(ABEO.US)$
fda rejected their drug based mainly on the manufacturing. They didnt say no to the drug, they just said they need to know more about the process of making it. Hopefully by the end of next month they will have it all in order. GL if you get in, i would wait for 2 more days of down before i buy any. complete gamble on this one

Trytosaveabit

04/23 07:06

Damn! Hehehe

$アベオナ・セラピューティクス(ABEO.US)$ Could be a buy opportunity? NFA! just thinking outloud

Trytosaveabit

04/23 04:09

$アベオナ・セラピューティクス(ABEO.US)$ Abeona Therapeutics Anticipates Completing And Submitting Requested CMC Information In Q3 2024 Abeona Therapeutics Inc - No New Clinical Studies Requested by FDA to Support Approval

Trytosaveabit

04/23 04:08

Grr

$アベオナ・セラピューティクス(ABEO.US)$ Abeona Therapeutics Inc: Receives FDA Complete Response Letter (Crl) Based on Need for Additional Cmc Information. Abeona Therapeutics Inc - Crl Did Not Identify Deficiencies Related to Clinical Efficacy or Clinical Safety Data in Bla

Meltyy

03/28 19:44

Upcoming Cell & Gene Therapy PDUFA’s in 2024

Several highly anticipated PDUFA decisions are approaching..👇
Abeona Therapeutics ($アベオナ・セラピューティクス(ABEO.US)$ )
Asset: Pz-cel (prademagene zamikeracel)
PDUFA Date: May 25, 2024
Indication: Recessive dystrophic epidermolysis bullosa (RDEB)
Technology: Autologous cell therapy, treatment uses gene transfer to deliver COL7A1 genes into an RDEB patient’s own skin cells then transplanting them back to the patient.
Rocket Pharmaceuticals ($ロケット・ファーマシューティカルズ(RCKT.US)$ )...

まだコメントはありません

分析

アナリスト評価

データなし

目標株価

データなし

ホット

米国株

総合人気